Medtronic Initiates Final Steps to Spin Off Majority Stake in MiniMed
Medtronic has begun the final phase of separating its diabetes technology business, MiniMed. The company is offering shareholders a chance to exchange their Medtronic shares for MiniMed stock at a 7% discount as part of an ongoing two-step separation process that began when MiniMed went public in March 2026. MiniMed CEO Que Dallara emphasized the benefits of independence, including greater autonomy over capital allocation and product development. Analysts note this move aligns with Medtronic's strategic focus on cardiovascular, neuroscience, and surgical markets while freeing up resources for key growth areas like cardiac ablation and robotic surgery. The exchange offer is set to expire on October 9, after which Medtronic may sell its remaining stake if demand exceeds supply. Since going public, MiniMed shares have risen by approximately 18%, reaching $21.50 as of September 14.
Tickers: $MDT
Topics: corporate restructuring MiniMed spin-off stock exchange offer